^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ultra-high concentration nitric oxide (UNO101)

    i
    Other names: UNO101, UNO, gNO
    Associations

    News

    Trials
    Company:
    Beyond Air
    Drug class:
    Immunostimulant, Guanylate cyclase stimulant, Nitric oxide donor
    Related drugs:
    Associations

    News

    Trials
    3ms
    A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Beyond Air Inc. | Trial completion date: Apr 2025 --> Jun 2025 | Trial primary completion date: Jul 2024 --> May 2025
    Trial completion date • Trial primary completion date • Metastases
    |
    ultra-high concentration nitric oxide (UNO101)
    7ms
    A Study to Assess the Safety and Efficacy of Nitric Oxide Injection Into Unresectable Solid Primary or Metastatic Tumors (clinicaltrials.gov)
    P1, N=38, Recruiting, Beyond Air Inc. | Trial completion date: Jul 2024 --> Apr 2025 | Trial primary completion date: Dec 2023 --> Jul 2024
    Trial completion date • Trial primary completion date • Metastases
    |
    ultra-high concentration nitric oxide (UNO101)
    1year
    Intratumoral Administration of High-Concentration Nitric Oxide and Anti-mPD-1 Treatment Improves Tumor Regression Rates and Survival in CT26 Tumor-Bearing Mice. (PubMed, Cells)
    Combining high-concentration NO and immune checkpoint inhibitors warrants further assessment especially in tumors resistant to checkpoint inhibitor therapy.
    Preclinical • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1) • CD8 (cluster of differentiation 8)
    |
    PD-L1 expression
    |
    ultra-high concentration nitric oxide (UNO101)
    over2years
    Single intra-tumoral injection of gaseous nitric oxide induces an adaptive immune response in a mouse CT-26 solid tumor model (AACR 2022)
    Intra-tumoral injection of ultra-high doses of NO at 20,000 and 50,000 ppm gNO led to an increased recruitment and concentration of T and B cells. Additionally, 50,000 ppm NO led to an increase of lymphocyte infiltration to the tumor. Taken together, the data suggest that the increase in lymphocyte infiltration, B and T cell population, and the reduction of MDSCs, are indicative of an adaptive immune response that results in rejection of secondary tumors in gNO-treated mice.
    Preclinical
    |
    IFNG (Interferon, gamma)
    |
    IFNG expression
    |
    ultra-high concentration nitric oxide (UNO101)